Literature DB >> 21498106

Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas.

Balázs Szabó1, Györgyi A Nelhubel, Adél Kárpáti, István Kenessey, Balázs Jóri, Csilla Székely, István Peták, Gábor Lotz, Zita Hegedus, Balázs Hegedus, Tibor Füle, Balázs Döme, József Tímár, József Tóvári.   

Abstract

The significance of epidermal growth factor receptor (EGFR) signaling is well studied in a number of different tumors, but limited data is available with regard to head and neck squamous cell carcinoma (HNSCC). Since anti-EGFR therapies are currently under investigation in these malignancies as well, comprehensive information about the alteration of EGFR in HNSCC is necessary to design the most appropriate therapeutic protocols. We examined retrospectively the gene copy number of EGFR by FISH and the protein expression by immunohistochemistry using different epitope-specific antibodies in paraffin-embedded primary tumors of five different regions, from 71 HNSCC patients who had not been treated with anti-EGFR therapy. In seven cases corresponding lymph node metastases were also available for comparative analyses. We also determined the mutational status of tyrosine kinase (TK) domain (exon 19 and 21) and the extracellular deletion mutation (vIII) of EGFR, the KRAS mutation at codon 12 and the presence of HPV infection. Eight of the 71 cases (11.3%) showed EGFR gene amplification (most of them localized into the hypopharyngeal region) and the increased gene copy number (amplification+polysomy) was 43.7%. Despite pronounced intratumoral heterogeneity of EGFR protein expression being found, the high EGFR expression correlated with poor prognosis. On the other hand, the phosphorylation of EGFR was associated with prolonged survival. No mutations in the TK domain of EGFR were found in any of the HNSCC patients and only two cases were KRAS mutant at codon 12. We detected vIII deletion mutation of EGFR in 21% of the samples, but there was no statistically significant correlation between the presence of vIII mutant form and patient survival. EGFR vIII mutation was, however, associated with increased gene copy number. Fourteen of 71 cases (19.7%) were HPV-positive and the incidence of infection showed a decreasing tendency from the oral cavity towards the larynx. Interestingly, in contrast to previous findings, we could not observe improved survival in HPV-positive patients compared to non-infected patients, most probably due to the fact that the majority of these HNSCC patients were smokers and alcohol consumers. In conclusion, we found that increased EGFR protein levels and gene copy numbers (not gene amplification alone) have prognostic significance in the investigated HNSCC patient population. However, the relatively high incidence of the EGFR-vIII mutant form warrants careful therapeutic decision-making when choosing between different anti-EGFR treatment options.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498106     DOI: 10.1016/j.oraloncology.2011.03.020

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  33 in total

1.  Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx.

Authors:  Satoshi Fujii; Hideoki Uryu; Ken Akashi; Kensuke Suzuki; Manabu Yamazaki; Makoto Tahara; Ryuichi Hayashi; Atsushi Ochiai
Journal:  Int J Clin Oncol       Date:  2012-03-24       Impact factor: 3.402

Review 2.  Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.

Authors:  Christos Perisanidis
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

Review 3.  At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone.

Authors:  John Foley; Nicole Nickerson; David J Riese; Peter C Hollenhorst; Gwendolen Lorch; Anne M Foley
Journal:  Odontology       Date:  2012-06-10       Impact factor: 2.634

Review 4.  Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Authors:  Carolien Boeckx; Marc Baay; An Wouters; Pol Specenier; Jan B Vermorken; Marc Peeters; Filip Lardon
Journal:  Oncologist       Date:  2013-07-02

5.  The prognostic role of claudins in head and neck squamous cell carcinomas.

Authors:  Györgyi A Nelhűbel; Boróka Károly; Balázs Szabó; Gábor Lotz; András Kiss; József Tóvári; István Kenessey
Journal:  Pathol Oncol Res       Date:  2013-07-12       Impact factor: 3.201

6.  Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.

Authors:  Shoude Zhang; Jia Chen; Hua Jiang; Haina Ma; Beibei Yang
Journal:  Eur J Clin Pharmacol       Date:  2012-01-10       Impact factor: 2.953

7.  Attenuation of EGFL7 inhibits human laryngocarcinoma cells growth and invasion.

Authors:  Xiao-Xia Wang; Xiao-Bao Yao; Zhang-Shao Qiang; Hong-Liang Zhu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

8.  Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.

Authors:  Christina I Tsien; Mukesh K Nyati; Aarif Ahsan; Susmita G Ramanand; Douglas B Chepeha; Francis P Worden; Joseph I Helman; Nisha D'Silva; Carol R Bradford; Gregory T Wolf; Theodore S Lawrence; Avraham Eisbruch
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

9.  Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma.

Authors:  Cara B Gonzales; Jorge J De La Chapa; Pothana Saikumar; Prajjal K Singha; Nicholas F Dybdal-Hargreaves; Jeffery Chavez; Aaron M Horning; Jamie Parra; Nameer B Kirma
Journal:  Oral Oncol       Date:  2016-08       Impact factor: 5.337

Review 10.  Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.

Authors:  Jennifer L Hunt; Leon Barnes; James S Lewis; Magdy E Mahfouz; Pieter J Slootweg; Lester D R Thompson; Antonio Cardesa; Kenneth O Devaney; Douglas R Gnepp; William H Westra; Juan P Rodrigo; Julia A Woolgar; Alessandra Rinaldo; Asterios Triantafyllou; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-07       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.